Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

Abstract: Provided herein, inter alia, are methods of detecting 3? flap Okazaki fragments for treating and diagnosing cancer.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: The present invention belongs to the field of antibody drugs, and relates to a humanized anti-VEGFR2 single-chain antibody and use thereof. The single-chain antibody comprises a heavy chain variable region set forth in SEQ ID No. 1 and a light chain variable region set forth in SEQ ID No. 2, wherein the heavy chain variable region and the light chain variable region are connected via a flexible peptide with an amino acid sequence set forth in SEQ ID No. 3. The present invention also discloses use of the antibody in preparing a product for inhibiting tumor growth. The antibody disclosed herein can be used as a medicament for clinical use in indications caused by neovascularization.

Abstract: Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: FEN-1 is involved in processing HIV central DNA flap (CDF) and is a target for intervention of HIV-1 replication. Inhibition of HIV-1 CDF removal by expression of D181A FEN-1 mutant suppresses viral DNA replication, further demonstrating that FEN-1 is a target. Methods of identifying and using molecules that inhibit FEN-1 processing HIV-1 CDF and other methods of inhibiting FEN-1 processing are provided. Useful small molecules specifically suppress FEN-1 cleavage of HIV CDF but have little effect on FEN-1's function in RNA-DNA primer removal. Pentamidine inhibits HIV replication by suppressing FEN-1-mediated HIV-CDF processing.

Abstract: FEN-1 is involved in processing HIV central DNA flap (CDF) and is a target for intervention of HIV-1 replication. Inhibition of HIV-1 CDF removal by expression of D181A FEN-1 mutant suppresses viral DNA replication, further demonstrating that FEN-1 is a target. Methods of identifying and using molecules that inhibit FEN-1 processing HIV-1 CDF and other methods of inhibiting FEN-1 processing are provided. Useful small molecules specifically suppress FEN-1 cleavage of HIV CDF but have little effect on FEN-l's function in RNA-DNA primer removal. Pentamidine inhibits HIV replication by suppressing FEN-1-mediated HIV-CDF processing.